UNSPSC 51451601: Cambendazole

This classification denotes an antihelminthic agent with the molecular formula C14H14N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 079X63S3DU, chemically known as 5-benzimidazolecarbamic acid, 2-(4-thiazolyl)-, isopropyl ester but generally known as cambendazole, which bears US NIH Compound Identifier 33309. Cambendazole most often comes in base and methyl ester forms. European Medicines Agency schedules Cambendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06062MIG.

UNSPSC 51451601 Cambendazole, a Commodity code, does not reflect the actual scope of state and local procurement activity currently solicited under this taxonomy entry. Recent opportunities posted under the code involve naloxone kits, medical and first aid supplies for emergency response, generic pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription programs—none of which are cambendazole or anthelmintic products. The mismatch suggests either a data-tagging error in the source system or category misalignment. The issuing bodies span county health departments, municipal fire services, state health and human services agencies, and multi-state cooperative purchasing alliances, indicating broad-based procurement across health and emergency response functions. When opportunities are actually bought under pharmaceutical and medical-supply codes at the commodity tier, they typically involve bulk volumes with firm pricing, established wholesaler channels, compliance with FDA and cGMP standards, and delivery schedules tied to public-health operations.

Recent activity includes Seminole County, Florida's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (due July 26, 2023); the City of Tampa's sheltered-market IFB for 169 line items of medical and first aid supplies for the Fire Department (due March 13, 2026, with an estimated contract value of $700,000); the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across state and local facilities (due March 26, 2026); and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026). Geographic activity centers on Florida, Texas, and Minnesota, with cooperative purchasing extending into Oregon. Procurement activity is current and active, though the code's nominal scope does not align with what state and local buyers are actually pursuing under it.